Skip to main content

Table 2 MRI signal and tumor characteristics of HCC target lesions at baseline and follow-up

From: Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib

Pat. Dose
(mg)#
MRI-FU Lesion
(no.)
Size
(mm)
T1 T2 fs Necr. [NT]/[TV] (%) Sum
(mm)
1 - baseline liver 25 2 4 - - 25
  800 3 w. (1) 30 4 4 <25 30
  800 8 w.   30 2 5 <25 30
  800 16 w.   34 2 5 <25 34
2 - baseline liver 160 2 3 + <50 170
  400 2 w. (2) 165 4 5 <50 175
  800 6 w.   160 4 3 <75 172
  400 14 w.   155 2 3 >75 172
3 - baseline liver 35 2 4 - - 35
  800 2 w. (4) 35 2 4 - - 35
  200 6 w.   35 2 4 - - 35
  200 12 w.   39 4 3 <25 39
4 - baseline liver 57 3 4 + <25 57
  800 4 w. (1) 57 4 5 <25 57
5 - baseline liver 30 2 4 + <25 30
  800 2 w. (1) 30 2 4 <25 30
  800 6 w.   31 2 5 <25 31
  400 13 w.   30 2 5 <25 30
  400 20 w.   40 2 5 <25 40
6 - baseline liver 133 2 4 + <25 133
  800 3 w. (1) 135 3 5 <25 135
  800 7 w.   130 2 3 <25 130
7 - baseline liver 38 2 2 + <25 70
  800 2 w. (3) 45 5 4 >75 80
  - 8 w.   32 3 3 <50 66
  400 16 w.   32 3 3 <25 71
8 - baseline adrenal 45 3 3 + <25 144
  800 3 w. (3) 45 5 4 <25 144
  400 8 w.   57 5 4 <25 156
9 - baseline liver 20 2 4 - - 119
  800 5 w. (3) 22 4 5 >75 123
  800 14 w.   20 4 5 >75 119
  800 20 w.   20 2 4 >75 119
10 - baseline perit. 12 2 3 - - 12
  800 2 w. (2) 12 3 5 +* 12
  800 7 w.   6 3 3 +* 6
  400 15 w.   0 - - - - 0
  400 23 w.   0 - - - - 0
11 - baseline liver 10 2 4 - - 19
  800 3 w. (2) 14 2 4 - - 26
  800 7 w.   17 2 4 - - 31
  800 15 w.   18 2 4 - - 35
  800 22 w.   21 2 4 - - 38
12 - baseline adrenal 15 2 4 + <25 50
  800 4 w. (2) 12 2 4 <50 42
  800 12 w.   8 2 5 <50 36
  200 19 w.   8 2 5 <50 38
13 - baseline liver 38 3 4 + <25 38
  400 3 w. (1) 38 3 3 <25 38
  - 7 w.   55 4 3 <25 55
  200 15 w.   39 3 3 <50 39
14 - baseline liver 17 5 2 + <25 70
  800 2 w. (2) 17 5 2 <25 70
  800 5 w.   17 5 2 <50 70
  200 15 w.   17 5 2 <50 70
  400 23 w.   17 5 2 >75 70
15 - baseline bone 45 4 2 - - 149
  800 5 w. (3) 55 5 4 >75 176
  800 9 w.   45 4 5 >75 193
  800 16 w.   44 4 4 >75 172
  800 21 w.   45 5 4 >75 168
  800 24 w.   50 5 3 >75 163
  800 32 w.   60 4 3 >75 172
16 - baseline liver 52 4 2 + <25 83
  400 3 w. (2) 52 4 2 <25 83
  - 9 w.   52 3 2 <25 83
17 - baseline liver 51 1 4 + <25 93
  800 4 w. (2) 57 4 5 >75 107
18 - baseline liver 120 1 4 + <50 120
  800 7 w. (1) 130 1 4 <50 130
19 - baseline liver 151 1 4 + <25 201
  400 6 w. (2) 155 4 2 <50 210
  800 18 w.   165 5 5 >75 229
20 - baseline liver 15 3 3 - - 15
  400 2 w. (1) 15 5 4 <50 15
21 - baseline liver 62 2 4 - - 88
  400 8 w. (2) 75 4 5 <50 97
  200 15 w.   75 4 5 <50 97
  200 22 w.   81 3 3 <50 96
  200 29 w.   98 5 5 <50 113
  1. Abbreviations:
  2. Pat.: patient number. #Daily dose at the time point of each MRI imaging study. MRI-FU: MRI at follow-up;
  3. w.: week after therapy initiation. Lesion: location of representative analysed lesion and number of total lesions at this location. Size: size of the representative tumor lesion im mm. T1: T1-weighted image. T2fs: T2-weighted fat saturated image. Qualitative assessment of signal in relation to the signal of liver parenchyma (1 = markedly hypointense; 2 = slightly hypointense; 3 = isointense; 4 = slightly hyperintense; 5 = markedly hyperintense).
  4. PV: portal vein; perit.: peritoneal. Gd: Gadolinium-enhancement at baseline and its evolution at follow-up
  5. (↑ = increase; ↓ = decrease; ↔ = unchanged; (-) no necrosis detectable; (+) necrosis at baseline detectable). [NT]/[TV]% = percentage of necrosis volume to total tumor volume, expressed as a score with (--) no necrosis, <25%, <50%, <75%, or >75%. Sum (mm) = sum of the diameter of all detectable lesions at this location.
  6. +* = the necrotic areas could not be reliably quantified.